Boosting Biotechnology with Jobs and Innovation
GenScript Biotech has officially opened its US$15 million manufacturing facility in Singapore, marking a significant milestone for the company and the city-state’s biotechnology landscape. This facility, which will serve as GenScript’s Asia Pacific headquarters, is expected to generate nearly 100 new jobs across research, development, production, and supply chain functions. Career opportunities include roles for scientists, lab technicians, logistics specialists, and other positions within the commercial and laboratory sectors.
Advancing Local Biotech Capabilities
Situated at Solaris @ Kallang and spanning 30,000 square feet, the new facility represents GenScript’s first manufacturing venture in Singapore. It will play a crucial role in advancing cell and gene therapy, vaccine development, and the production of life sciences innovations. By manufacturing products locally, GenScript aims to accelerate turnaround times for vaccines and therapeutic developments, reducing reliance on overseas shipping.
The facility’s launch builds on GenScript’s previous contributions to Singapore’s biotech ecosystem. During the Covid-19 pandemic, the company collaborated with Duke-NUS and A*Star’s Diagnostics Development Hub to create cPass, the first Covid-19 neutralising antibody test kit approved for regulatory use, now deployed in 64 countries, including the US, UK, and Germany.
Collaborative Efforts for Growth
In addition to the facility opening, GenScript signed a memorandum of understanding with A*Star’s Diagnostics Development Hub. The partnership aims to develop talent within the biotech sector and manufacture diagnostic kits for disease detection, further enhancing Singapore’s diagnostics and life sciences supply chain.
Minister of State for Trade and Industry Alvin Tan, a guest speaker at the virtual ceremony, highlighted the importance of this collaboration. He emphasised that initiatives like these contribute to Singapore’s Manufacturing 2030 vision of becoming a global hub for advanced manufacturing, innovation, and talent.
This expansion underscores GenScript’s commitment to bolstering Singapore’s position as a key player in the Asia Pacific biotechnology sector while supporting global advancements in life sciences.
